Elizabeth Yamashita
Keine laufenden Positionen mehr
Profil
Elizabeth Yamashita worked as a Group Director-Global Regulatory Sciences & CMC at Bristol Myers Squibb Co. from 2000 to 2006.
She then worked as a Vice President-Regulatory CMC & Operations at ImClone LLC from 2006 to 2011.
From 2011 to 2012, she worked as a Vice President-CMC Regulatory at Savient Pharmaceuticals, Inc. She then worked as a Group Vice President-Regulatory Affairs at Savient Pharmaceuticals, Inc. from 2012 to 2014.
Finally, she worked as a Vice President-Regulatory Affairs at Outlook Therapeutics, Inc. Ms. Yamashita received an undergraduate degree from the University of Rochester.
Ehemalige bekannte Positionen von Elizabeth Yamashita
| Unternehmen | Position | Ende |
|---|---|---|
| SAVIENT PHARMACEUTICALS INC | Corporate Officer/Principal | 01.01.2014 |
| SAVIENT PHARMACEUTICALS INC | Corporate Officer/Principal | 01.10.2012 |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | 01.06.2011 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2006 |
| OUTLOOK THERAPEUTICS, INC. | General Counsel | - |
Ausbildung von Elizabeth Yamashita
| Rochester Christian University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| OUTLOOK THERAPEUTICS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
